Follow The Filings

VYGR Voyager Therapeutics Inc.

Health Care, filed as VOYAGER THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.4%
  • $4.1M
  • 1 add

In 2026 Q2 James Silverman added to Voyager Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Add 0.38%

Who owns VYGR

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.38% Add +3.0% 1,185,000 $4.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by VYGR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VYGR insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 11 sales to cover taxes and 6 stock grants.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,8.01 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $250.01M $80M $40.37M
Net income $132.33M -$65M -$119.72M
Net margin * 52.9% -81.3% -296.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $319.68M $276.81M $202.69M
Total non-current assets * $31.6M $116.24M $49.59M
Total assets $351.28M $393.05M $252.28M
Total current liabilities $64.51M $49.79M $26.54M
Total non-current liabilities * $50.45M $43.5M $29.66M
Total equity $236.32M $299.76M $196.08M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $77.92M -$15.31M -$132.47M
Cash from investing -$141.64M -$94.86M $125.45M
Cash from financing $33.64M $114.02M $0.816M
Net change in cash -$30.08M $3.85M -$6.2M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.